Technical Analysis for WVE - WAVE Life Sciences Ltd.

Grade Last Price % Change Price Change
D 7.24 -3.08% -0.23
WVE closed down 3.08 percent on Friday, June 11, 2021, on approximately normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Up
Historical WVE trend table...

Date Alert Name Type % Chg
Bearish Engulfing Bearish 0.00%
Stochastic Sell Signal Bearish 0.00%
Weak + Overbought Other 0.00%
Outside Day Range Expansion 0.00%
Weak, Overbought and Reversal Signs Reversal 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
180 Bullish Setup Bullish Swing Setup -3.08%
Pocket Pivot Bullish Swing Setup -3.08%
Slingshot Bullish Bullish Swing Setup -3.08%
Older End-of-Day Signals for WVE ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

WAVE Life Sciences Ltd. Description

WAVE Life Sciences Pte. Ltd., a preclinical biopharmaceutical company, designs, develops, and commercializes nucleic acid therapeutic candidates. The company is developing nucleic acid therapeutics that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. Its advanced therapeutic programs are in Huntington's disease, Duchenne muscular dystrophy (DMD), and inflammatory bowel disease (IBD). In Huntington's disease, it has programs targeting HTT SNP-1 and HTT SNP-2; in DMD, targeting Exon 51; and in IBD, targeting SMAD7. The company also has product candidates in its programs targeting HTT SNP-1 and Exon 51. In addition, it has late-stage discovery programs in epidermolysis bullosa simplex, targeting KRT14 SNP-1 and KRT14 SNP-2, as well as in DMD, focuses on an additional DMD target, AcRIIb. The company was founded in 2012 and is based in Singapore.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Acid Rare Diseases Dysfunction Medical Genetics Inflammatory Bowel Disease Dystrophy Muscular Dystrophy Huntington's Disease Genodermatoses Duchenne Muscular Dystrophy Duchenne Genetic Genealogy Epidermolysis Bullosa Cytoskeleton Dystrophin SNP

Is WVE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 19.98
52 Week Low 4.82
Average Volume 781,796
200-Day Moving Average 8.83
50-Day Moving Average 6.41
20-Day Moving Average 6.83
10-Day Moving Average 7.03
Average True Range 0.42
ADX 23.53
+DI 22.14
-DI 13.15
Chandelier Exit (Long, 3 ATRs) 6.29
Chandelier Exit (Short, 3 ATRs) 6.72
Upper Bollinger Bands 7.48
Lower Bollinger Band 6.18
Percent B (%b) 0.82
BandWidth 19.07
MACD Line 0.22
MACD Signal Line 0.14
MACD Histogram 0.0759
Fundamentals Value
Market Cap 353.15 Million
Num Shares 48.8 Million
EPS -5.15
Price-to-Earnings (P/E) Ratio -1.41
Price-to-Sales 24.43
Price-to-Book 4.03
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.98
Resistance 3 (R3) 8.00 7.77 7.85
Resistance 2 (R2) 7.77 7.59 7.76 7.81
Resistance 1 (R1) 7.51 7.47 7.40 7.49 7.77
Pivot Point 7.28 7.28 7.23 7.27 7.28
Support 1 (S1) 7.02 7.10 6.91 7.00 6.71
Support 2 (S2) 6.79 6.98 6.78 6.67
Support 3 (S3) 6.53 6.79 6.63
Support 4 (S4) 6.51